Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Robert John Motzer, Romain Banchereau, Habib Hamidi et al. · Cancer Cell · 2020
Cited by 569 works. doi:10.1016/j.ccell.2020.10.011
Authors
- Robert John Motzer
- Romain Banchereau
- Habib Hamidi
- Thomas B. Powles
- David F. McDermott
- Michael B. Atkins
- Bernard J. Escudier
- Ning Leng
- Alexander R. Abbas
- Jinzhen Fan
- Hartmut Koeppen
- Jennifer Lin
- Susheela Carroll
- Kenji Hashimoto
- Sanjeev Mariathasan
- Marjorie Green
- Darren Tayama
- Priti S. Hegde
- Christina Schiff
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Cancer statistics, 2018
- The Molecular Signatures Database Hallmark Gene Set Collection
- Mutations of the VHL tumour suppressor gene in renal carcinoma
- Fast and SNP-tolerant detection of complex variants and splicing in short reads
- The Reactome pathway Knowledgebase
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing